Want to see HK:1681 full AI Analyst Report?
Consun Pharmaceutical Group Ltd. (1681) Ratios
Consun Pharmaceutical Group Ltd. Ratios
HK:1681's free cash flow for Q2 2026 was $796.08M. For the 2026 fiscal year, HK:1681's free cash flow was decreased by $-28.21M and operating cash flow was $824.29M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.22 | 3.32 | 2.86 | 2.68 | 2.25 |
| Quick Ratio | 3.03 | 3.11 | 2.62 | 2.47 | 2.06 |
| Cash Ratio | 0.89 | 2.12 | 1.84 | 1.81 | 1.62 |
| Solvency Ratio | 0.73 | 0.67 | 0.54 | 0.52 | 0.45 |
| Operating Cash Flow Ratio | 0.85 | 0.79 | 0.55 | 0.70 | 0.53 |
| Short-Term Operating Cash Flow Coverage | 6.06 | 4.29 | 1.63 | 2.10 | 1.21 |
| Net Current Asset Value | $ 3.05B | $ 3.09B | $ 2.69B | $ 2.17B | $ 1.60B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.05 | 0.09 | 0.09 | 0.14 |
| Debt-to-Equity Ratio | 0.05 | 0.07 | 0.14 | 0.15 | 0.23 |
| Debt-to-Capital Ratio | 0.04 | 0.06 | 0.12 | 0.13 | 0.19 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.41 | 1.43 | 1.52 | 1.56 | 1.67 |
| Debt Service Coverage Ratio | 5.44 | 3.39 | 1.69 | 1.57 | 1.01 |
| Interest Coverage Ratio | 275.77 | 41.99 | 41.62 | 69.27 | 54.92 |
| Debt to Market Cap | 0.02 | 0.04 | 0.15 | 0.16 | 0.21 |
| Interest Debt Per Share | 0.25 | 0.36 | 0.67 | 0.60 | 0.78 |
| Net Debt to EBITDA | -0.87 | -2.52 | -2.32 | -2.53 | -2.18 |
| Profitability Margins | |||||
| Gross Profit Margin | 78.05% | 75.56% | 74.19% | 75.35% | 74.70% |
| EBIT Margin | 33.71% | 32.86% | 34.17% | 30.58% | 32.29% |
| EBITDA Margin | 35.66% | 35.27% | 37.18% | 33.59% | 35.64% |
| Operating Profit Margin | 35.18% | 35.22% | 34.17% | 32.37% | 34.66% |
| Pretax Profit Margin | 35.01% | 34.38% | 33.35% | 31.90% | 34.03% |
| Net Profit Margin | 31.55% | 30.68% | 30.29% | 29.19% | 28.86% |
| Continuous Operations Profit Margin | 31.87% | 30.92% | 30.37% | 29.22% | 28.71% |
| Net Income Per EBT | 90.11% | 89.25% | 90.83% | 91.49% | 84.81% |
| EBT Per EBIT | 99.50% | 97.61% | 97.60% | 98.56% | 98.18% |
| Return on Assets (ROA) | 16.81% | 15.56% | 14.24% | 13.96% | 13.53% |
| Return on Equity (ROE) | 23.76% | 22.22% | 21.63% | 21.71% | 22.55% |
| Return on Capital Employed (ROCE) | 24.14% | 23.32% | 22.05% | 21.38% | 23.58% |
| Return on Invested Capital (ROIC) | 21.08% | 19.82% | 17.83% | 17.70% | 17.08% |
| Return on Tangible Assets | 17.54% | 16.30% | 15.02% | 14.91% | 14.68% |
| Earnings Yield | 8.97% | 14.49% | 22.67% | 24.15% | 20.55% |
| Efficiency Ratios | |||||
| Receivables Turnover | 9.63 | 9.97 | 10.12 | 9.01 | 5.82 |
| Payables Turnover | 10.05 | 9.59 | 8.04 | 9.63 | 7.76 |
| Inventory Turnover | 2.76 | 2.50 | 1.82 | 2.00 | 2.01 |
| Fixed Asset Turnover | 3.52 | 3.21 | 3.00 | 2.67 | 2.38 |
| Asset Turnover | 0.53 | 0.51 | 0.47 | 0.48 | 0.47 |
| Working Capital Turnover Ratio | 1.08 | 1.00 | 1.02 | 1.18 | 1.35 |
| Cash Conversion Cycle | 133.67 | 144.34 | 191.12 | 184.64 | 197.45 |
| Days of Sales Outstanding | 37.88 | 36.60 | 36.05 | 40.49 | 62.70 |
| Days of Inventory Outstanding | 132.10 | 145.81 | 200.45 | 182.05 | 181.76 |
| Days of Payables Outstanding | 36.31 | 38.08 | 45.38 | 37.90 | 47.02 |
| Operating Cycle | 169.98 | 182.42 | 236.50 | 222.55 | 244.46 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.42 | 1.32 | 1.02 | 1.20 | 0.91 |
| Free Cash Flow Per Share | 1.34 | 1.19 | 0.96 | 1.13 | 0.78 |
| Dividend Paid and CapEx Coverage Ratio | 2.14 | 1.38 | 2.16 | 5.29 | 2.45 |
| Capital Expenditure Coverage Ratio | 17.70 | 9.97 | 15.58 | 18.37 | 7.38 |
| Operating Cash Flow Coverage Ratio | 5.69 | 4.07 | 1.60 | 2.06 | 1.19 |
| Operating Cash Flow to Sales Ratio | 0.35 | 0.37 | 0.32 | 0.41 | 0.35 |
| Free Cash Flow Yield | 9.52% | 15.56% | 22.15% | 31.69% | 21.84% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 11.15 | 6.90 | 4.41 | 4.14 | 4.87 |
| Price-to-Sales (P/S) Ratio | 3.52 | 2.12 | 1.34 | 1.21 | 1.40 |
| Price-to-Book (P/B) Ratio | 2.65 | 1.53 | 0.95 | 0.90 | 1.10 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 10.51 | 6.43 | 4.51 | 3.16 | 4.58 |
| Price-to-Operating Cash Flow Ratio | 9.91 | 5.78 | 4.22 | 2.98 | 3.96 |
| Price-to-Earnings Growth (PEG) Ratio | 0.83 | 0.52 | 0.32 | 0.26 | 0.23 |
| Enterprise Value Multiple | 8.98 | 3.48 | 1.27 | 1.07 | 1.77 |
| Enterprise Value | 10.95B | 3.64B | 1.22B | 837.40M | 1.29B |
| EV to EBITDA | 8.98 | 3.48 | 1.27 | 1.07 | 1.77 |
| EV to Sales | 3.20 | 1.23 | 0.47 | 0.36 | 0.63 |
| EV to Free Cash Flow | 9.58 | 3.73 | 1.60 | 0.93 | 2.05 |
| EV to Operating Cash Flow | 9.03 | 3.35 | 1.49 | 0.88 | 1.77 |
| Tangible Book Value Per Share | 5.36 | 5.02 | 4.54 | 3.96 | 3.21 |
| Shareholders’ Equity Per Share | 5.31 | 4.99 | 4.53 | 3.98 | 3.27 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.09 | 0.10 | 0.09 | 0.08 | 0.16 |
| Revenue Per Share | 4.00 | 3.61 | 3.24 | 2.96 | 2.55 |
| Net Income Per Share | 1.26 | 1.11 | 0.98 | 0.86 | 0.74 |
| Tax Burden | 0.90 | 0.89 | 0.91 | 0.91 | 0.85 |
| Interest Burden | 1.04 | 1.05 | 0.98 | 1.04 | 1.05 |
| Research & Development to Revenue | 0.04 | 0.03 | 0.04 | 0.05 | 0.05 |
| SG&A to Revenue | 0.44 | 0.44 | 0.12 | 0.14 | 0.14 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | -0.00 | 0.01 |
| Income Quality | 1.01 | 1.07 | 0.95 | 1.39 | 1.23 |
Currency in CNY
